CurrentCardio
Get Weekly

Prevention & lipidsRandomised controlled trial

Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid (RESPECT-EPA)

CirculationPublished

  • Randomised controlled trial
  • prospective
  • multicentre
  • open-label
  • blinded end-point
Read the original article ↗

Authors' conclusion

Icosapent ethyl treatment resulted in a numerically lower risk of cardiovascular events that did not reach statistical significance in patients with chronic coronary artery disease, a low EPA/AA ratio, and statin treatment.

Study context

Population
Patients with stable CAD, a low eicosapentaenoic acid (EPA)/AA ratio (<0.4) and statin treatment, 95 sites in Japan3,884 enrolled
Participants
2,506 patients
Comparison
Icosapent ethyl vs control
  • EPAn = 1,249
  • Controln = 1,257reference
Primary endpoint
Composite of:
  • CV death
  • Nonfatal MI
  • Nonfatal ischemic stroke
  • Unstable angina pectoris
  • Coronary revascularization
Follow-up
Median 5 years

Primary result

As reported in the abstract

Hazard ratio

0.79

95% CI 0.62–1.00

P = 0.055

Events by treatment group

EPA vs Control
HR 0.79 (95% CI 0.62–1.00); P = 0.055

Further findings

OutcomeEPAControlHR (95% CI)
Composite of coronary events6.6%9.7%0.73 (0.55–0.97)

Median

OutcomeEPAControlEstimate
EPA/AA ratio (baseline)0.243 (IQR 0.180–0.314)0.235 (IQR 0.163–0.310)

Safety

New-onset AF

P = 0.017

Adverse events

Adverse events did not differ between the groups

Original publication

Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation. Published 14 June 2024. doi:10.1161/circulationaha.123.065520
Read the original article ↗PubMedCite RIS · BibTeX

Summarised from the published abstract; every number is checked against it